We have observed an unprecedented demand for Tocilizumab (Brand: Actemra) given the significant increase in Covid cases across India in the last few weeks.
We are responding to this situation with supplies over this and the coming weeks to meet the immediate emergency demand. However, we are mindful that the current unprecedented demand may far exceed the supplies we can provide at this moment.
We are working urgently to increase manufacturing capacity and supply by ramping up our own production network, as well as actively collaborating with external partners to maximize production of Actemra wherever possible with the goal of increasing its availability. This should enable us to meet future demand in a fluid and hard to predict environment.
In India we have partnered with Cipla for the marketing and distribution of Tocilizumab (Actemra)